AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Building a retirement portfolio of $1 million or more is within reach for many Americans. AbbVie (NYSE: ABBV) is a great ...

Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

For his work in 2024, AbbVie helmsman Robert Michael—who took over as CEO from Richard Gonzalez on July 1—collected nearly $18.5 million in total pay.

AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational ...

Abbott Laboratories is a diverse healthcare stock with a fantastic dividend. AbbVie is a Dividend King that has demonstrated its ability to successfully navigate challenges. Johnson & Johnson is a ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...